Guggenheim Maintains Buy on CG Oncology, Raises Price Target to $120
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Guggenheim analyst Michael Schmidt maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $89 to $120.
Guggenheim analyst Michael Schmidt maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $89 to $120.
